NCT04857983View on ClinicalTrials.gov

Memantine Augmentation of Targeted Cognitive Training in Schizophrenia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

July 6, 2021

Primary Completion Date

March 30, 2025

Study Completion Date

March 30, 2025

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

Memantine

Subjects will be assigned to take memantine or placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance

DRUG

Placebo

Subjects will be assigned to take memantine or placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance

Trial Locations (1)

92103

Clinical Teaching Facility (CTF B-403 at UCSD Medical Center), San Diego

All Listed Sponsors
lead

University of California, San Diego

OTHER